TY - JOUR
T1 - Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia
AU - van der Flier, Wiesje M.
AU - de Vugt, Marjolein E.
AU - Smets, Ellen M. A.
AU - Blom, Marco
AU - Teunissen, Charlotte E.
N1 - Funding Information: The authors are work package leads on the ABOARD project. ABOARD is a public–private partnership receiving funding from ZonMw (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance, LSHM20106). Partners in ABOARD are Amsterdam UMC, locations VUmc and AMC, MUMC+, Erasmus MC, UMC Radboud, UMCG, TU Delft, Inholland, Vilans, Pharos, HealthRI, Jeroen Bosch Ziekenhuis, Medisch Centrum Leeuwarden, Zorg Innovatie Forum, Pharmo–STIZON, Alzheimer Nederland, Hersenstichting, KBO-PCOB, PGGM, Zorgverzekeraars Nederland, CZ, Zilveren Kruis, Neurocast, Philips, ADx NeuroSciences, Castor, Vereniging Innovatieve Geneesmiddelen, Roche NL, Biogen NL, Novartis NL and the Brain Research Center. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbis Fonds. W.M.v.d.F., E.M.A.S. and C.E.T. are project leads on TAP-Dementia, a ZonMw-funded project (10510032120003) to optimize diagnosis of dementia, part of the Dutch National Dementia Strategy. W.M.v.d.F. is a recipient of JPND-funded EU-FINGERS (ZonMw-Memorabel 733051102) and ADDITION (ZonMw 733051083). Research of Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by funding from Stichting Alzheimer Nederland and Stichting VUmc. The chair of W.M.v.d.F. is supported by the Pasman Stichting. Funding Information: The authors are work package leads on the ABOARD project. ABOARD is a public–private partnership receiving funding from ZonMw (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance, LSHM20106). Partners in ABOARD are Amsterdam UMC, locations VUmc and AMC, MUMC+, Erasmus MC, UMC Radboud, UMCG, TU Delft, Inholland, Vilans, Pharos, HealthRI, Jeroen Bosch Ziekenhuis, Medisch Centrum Leeuwarden, Zorg Innovatie Forum, Pharmo–STIZON, Alzheimer Nederland, Hersenstichting, KBO-PCOB, PGGM, Zorgverzekeraars Nederland, CZ, Zilveren Kruis, Neurocast, Philips, ADx NeuroSciences, Castor, Vereniging Innovatieve Geneesmiddelen, Roche NL, Biogen NL, Novartis NL and the Brain Research Center. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbis Fonds. W.M.v.d.F., E.M.A.S. and C.E.T. are project leads on TAP-Dementia, a ZonMw-funded project (10510032120003) to optimize diagnosis of dementia, part of the Dutch National Dementia Strategy. W.M.v.d.F. is a recipient of JPND-funded EU-FINGERS (ZonMw-Memorabel 733051102) and ADDITION (ZonMw 733051083). Research of Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by funding from Stichting Alzheimer Nederland and Stichting VUmc. The chair of W.M.v.d.F. is supported by the Pasman Stichting. Publisher Copyright: © 2023, Springer Nature America, Inc.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Alzheimer’s disease (AD) is a major healthcare challenge with no curative treatment at present. To address this challenge, we need a paradigm shift, where we focus on pre-dementia stages of AD. In this Perspective, we outline a strategy to move towards a future with personalized medicine for AD by preparing for and investing in effective and patient-orchestrated diagnosis, prediction and prevention of the dementia stage. While focusing on AD, this Perspective also discusses studies that do not specify the cause of dementia. Future personalized prevention strategies encompass multiple components, including tailored combinations of disease-modifying interventions and lifestyle. By empowering the public and patients to be more actively engaged in the management of their health and disease and by developing improved strategies for diagnosis, prediction and prevention, we can pave the way for a future with personalized medicine, in which AD pathology is stopped to prevent or delay the onset of dementia.
AB - Alzheimer’s disease (AD) is a major healthcare challenge with no curative treatment at present. To address this challenge, we need a paradigm shift, where we focus on pre-dementia stages of AD. In this Perspective, we outline a strategy to move towards a future with personalized medicine for AD by preparing for and investing in effective and patient-orchestrated diagnosis, prediction and prevention of the dementia stage. While focusing on AD, this Perspective also discusses studies that do not specify the cause of dementia. Future personalized prevention strategies encompass multiple components, including tailored combinations of disease-modifying interventions and lifestyle. By empowering the public and patients to be more actively engaged in the management of their health and disease and by developing improved strategies for diagnosis, prediction and prevention, we can pave the way for a future with personalized medicine, in which AD pathology is stopped to prevent or delay the onset of dementia.
UR - http://www.scopus.com/inward/record.url?scp=85160109135&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s43587-023-00404-2
DO - https://doi.org/10.1038/s43587-023-00404-2
M3 - Article
C2 - 37202515
SN - 2662-8465
VL - 3
SP - 494
EP - 505
JO - Nature Aging
JF - Nature Aging
IS - 5
ER -